Matthew E. Ros's Insider Trades & SAST Disclosures
Matthew E. Ros's most recent trade in Verastem Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Matthew E. Ros.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Verastem Inc | Matthew E. Ros | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,051 | 3,051 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,743 | 1,743 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 1,900 | 1,900 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,792 | 1,792 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 1,419 | 1,419 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 2,194 | 2,194 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 2,650 | 2,650 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,256 | 2,256 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 2,463 | 2,463 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 2,225 | 2,225 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 2,068 | 2,068 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,641 | 1,641 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 9,247 | 9,247 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 35,280 | 35,280 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges